The anti-apoptotic and pro-proliferative functions of FLT3 mutations in AML cells indicate its potential as a molecular target, facilitating recent development of FLT3 protein tyrosine kinase inhibitors. This evidence concerns the gene FLT3 and acute myeloid leukemia.